Top

Journal of Experimental & Clinical Cancer Research

Published in:

01-12-2021 | Neuroblastoma | Research

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Authors: Lijia Pan, Cheng Cheng, Peiwen Duan, Kai Chen, Yeming Wu, Zhixiang Wu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

High-risk neuroblastoma patients have a 5-year survival rate of less than 50%. It’s an urgent need to identify new therapeutic targets and the appropriate drugs. Exportin-1 (XPO1), also known as chromosomal region maintenance 1, plays important roles in the progression of tumorigenesis. However, the prognostic and therapeutic values of XPO1 in neuroblastoma have not been reported.

Methods

Correlations between XPO1 expression level and clinical characteristics were analyzed using the Neuroblastoma Research Consortium (NRC) dataset and tissue microarray analysis. Cell proliferation assays, colony formation assays, apoptosis assays, cell cycle analysis were performed to analyze the anti-tumor effects of verdinexor (KPT-335) in vitro. Western blot and mRNA sequencing were performed to explore underlying mechanism. In vivo anti-tumor effects of verdinexor were studied in a neuroblastoma xenograft model.

Results

Higher XPO1 levels were associated with advanced stage and poor prognosis in neuroblastoma patients. The specific inhibitor of XPO1 verdinexor suppressed the neuroblastoma cell growth both in vitro and in vivo. Specifically, inhibition of XPO1 suppressed the neuroblastoma cell proliferation and induced cell apoptosis by nuclear accumulation of FOXO1 and RB1 in the neuroblastoma due to the inhibition of the PI3K/AKT pathway, and induced G0/G1 phase cell cycle arrest by activation of P53 function.

Conclusions

XPO1 is a promising prognostic indicator for neuroblastoma and a novel target for antitumor treatment with selective inhibitor verdinexor.

Available only for authorised users

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma Nat Rev Dis Primers. 2016;2:16078. https://doi.org/10.1038/nrdp.2016.78.CrossRefPubMed

Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–16. https://doi.org/10.1038/nrc1014.CrossRefPubMed

Pastor ER, Mousa SA. Current management of neuroblastoma and future direction. Crit Rev Oncol Hematol. 2019;138:38–43. https://doi.org/10.1016/j.critrevonc.2019.03.013.CrossRefPubMed

Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17:369–86. https://doi.org/10.1080/14737140.2017.1285230.CrossRefPubMed

Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, et al. The challenge of defining “ultra-high-risk” neuroblastoma. Pediatr Blood Cancer. 2019;66: e27556. https://doi.org/10.1002/pbc.27556.CrossRefPubMed

Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–411. https://doi.org/10.1038/nrc3526.CrossRefPubMedPubMedCentral

Ullman KS, Powers MA, Forbes DJ. Nuclear export receptors: from importin to exportin. Cell. 1997;90:967–70. https://doi.org/10.1016/s0092-8674(00)80361-x.CrossRefPubMed

Sun Q, Chen X, Zhou Q, Burstein E, Yang S, Jia D. Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal Transduct Target Ther. 2016;1:16010. https://doi.org/10.1038/sigtrans.2016.10.CrossRefPubMedPubMedCentral

Dong X, Biswas A, Süel KE, Jackson LK, Martinez R, Gu H, et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature. 2009;458:1136–41. https://doi.org/10.1038/nature07975.CrossRefPubMedPubMedCentral

10.

Senapedis WT, Baloglu E, Landesman Y. Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol. 2014;27:74–86. https://doi.org/10.1016/j.semcancer.2014.04.005.CrossRefPubMed

11.

Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell. 2012;23:3673–6. https://doi.org/10.1091/mbc.E12-01-0045.CrossRefPubMedPubMedCentral

12.

Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)–a novel class of anti-cancer agents. J Hematol Oncol. 2014;7:78. https://doi.org/10.1186/s13045-014-0078-0.CrossRefPubMedPubMedCentral

13.

Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155–65. https://doi.org/10.1038/leu.2013.115.CrossRefPubMed

14.

Breit MN, Kisseberth WC, Bear MD, Landesman Y, Kashyap T, McCauley D, et al. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines. BMC Vet Res. 2014;10:160. https://doi.org/10.1186/1746-6148-10-160.CrossRefPubMedPubMedCentral

15.

Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, et al. First-in-class, first-in-human phase i study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34:4142–50. https://doi.org/10.1200/jco.2015.65.3949.CrossRefPubMedPubMedCentral

16.

London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, et al. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS One. 2014;9: e87585. https://doi.org/10.1371/journal.pone.0087585.CrossRefPubMedPubMedCentral

17.

Sadowski AR, Gardner HL, Borgatti A, Wilson H, Vail DM, Lachowicz J, et al. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res. 2018;14:250. https://doi.org/10.1186/s12917-018-1587-9.CrossRefPubMedPubMedCentral

18.

Li R, Li Y, Kristiansen K, Wang J. SOAP: short oligonucleotide alignment program. Bioinformatics. 2008;24:713–4. https://doi.org/10.1093/bioinformatics/btn025.CrossRefPubMed

19.

Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357–60. https://doi.org/10.1038/nmeth.3317.CrossRefPubMedPubMedCentral

20.

Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9. https://doi.org/10.1038/nmeth.1923.CrossRefPubMedPubMedCentral

21.

Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323. https://doi.org/10.1186/1471-2105-12-323.CrossRefPubMedPubMedCentral

22.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8.CrossRefPubMedPubMedCentral

23.

Raivo K. pheatmap: Pretty Heatmaps. 2019. R package version 1.0.8. http://CRAN.R-project.org/package=pheatmap.

24.

Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH, et al. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer. 2015;15:395. https://doi.org/10.1186/s12885-015-1334-6.CrossRefPubMedPubMedCentral

25.

Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9. https://doi.org/10.1158/1078-0432.Ccr-04-0713.CrossRefPubMed

26.

Biggs WH 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A. 1999;96:7421–6. https://doi.org/10.1073/pnas.96.13.7421.CrossRefPubMedPubMedCentral

27.

Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintas-Cardama A, McDonnell TJ, et al. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 2014;105:795–801. https://doi.org/10.1111/cas.12430.CrossRefPubMedPubMedCentral

28.

Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res. 2001;61:8–13.PubMed

29.

Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, et al. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma. Br J Cancer. 2014;111:716–25. https://doi.org/10.1038/bjc.2014.325.CrossRefPubMedPubMedCentral

30.

Schwab TS, Madison BB, Grauman AR, Feldman EL. Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. Apoptosis. 2005;10:831–40. https://doi.org/10.1007/s10495-005-0429-y.CrossRefPubMed

31.

Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, et al. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the pediatric preclinical testing program. Pediatr Blood Cancer. 2016;63:276–86. https://doi.org/10.1002/pbc.25727.CrossRefPubMed

32.

Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther. 2015;153:25–35. https://doi.org/10.1016/j.pharmthera.2015.06.001.CrossRefPubMedPubMedCentral

33.

Cheng Y, Holloway MP, Nguyen K, McCauley D, Landesman Y, Kauffman MG, et al. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther. 2014;13:675–86. https://doi.org/10.1158/1535-7163.Mct-13-0416.CrossRefPubMedPubMedCentral

34.

Corno C, Stucchi S, De Cesare M, Carenini N, Stamatakos S, Ciusani E, et al. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models. Biochem Pharmacol. 2018;147:93–103. https://doi.org/10.1016/j.bcp.2017.11.009.CrossRefPubMed

35.

Kulkoyluoglu-Cotul E, Smith BP, Wrobel K, Zhao YC, Chen KLA, Hieronymi K, et al. Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance. Cancers (Basel). 2019;11. https://doi.org/10.3390/cancers11040479.

36.

Liu X, Chong Y, Tu Y, Liu N, Yue C, Qi Z, et al. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. J Hematol Oncol. 2016;9:108. https://doi.org/10.1186/s13045-016-0338-2.CrossRefPubMedPubMedCentral

37.

Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP, et al. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 2013;189:2317–26. https://doi.org/10.1016/j.juro.2012.10.018.CrossRefPubMed

38.

Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, et al. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells. PLoS One. 2014;9: e102983. https://doi.org/10.1371/journal.pone.0102983.CrossRefPubMedPubMedCentral

39.

Sun H, Hattori N, Chien W, Sun Q, Sudo M, GL EL, et al. KPT-330 has antitumour activity against non-small cell lung cancer. Br J Cancer. 2014;111:281–91. https://doi.org/10.1038/bjc.2014.260.CrossRefPubMedPubMedCentral

40.

Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D, et al. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018;18:335–45. https://doi.org/10.1016/j.clml.2018.03.003.CrossRefPubMed

41.

Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, et al. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020;13:148. https://doi.org/10.1186/s13045-020-00982-3.CrossRefPubMedPubMedCentral

42.

Marcus JM, Burke RT, Doak AE, Park S, Orth JD. Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death. Cell Cycle. 2018;17:1329–44. https://doi.org/10.1080/15384101.2018.1480224.CrossRefPubMedPubMedCentral

43.

Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 2003;197:93–8. https://doi.org/10.1016/s0304-3835(03)00088-0.CrossRefPubMed

44.

Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74:648–9. https://doi.org/10.1038/bjc.1996.415.CrossRefPubMedPubMedCentral

45.

Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A. 2013;110:1303–8. https://doi.org/10.1073/pnas.1217203110.CrossRefPubMedPubMedCentral

46.

Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood. 2018;131:855–63. https://doi.org/10.1182/blood-2017-08-797886.CrossRefPubMed

47.

Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, et al. nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis. Clin Cancer Res. 2019;25:2323–35. https://doi.org/10.1158/1078-0432.ccr-18-0959.CrossRefPubMed

48.

Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, et al. selective nuclear export inhibitor kpt-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer. Mol Cancer Ther. 2015;14:1570–81. https://doi.org/10.1158/1535-7163.Mct-15-0104.CrossRefPubMedPubMedCentral

Title: XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
Authors: Lijia Pan
Cheng Cheng
Peiwen Duan
Kai Chen
Yeming Wu
Zhixiang Wu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Neuroblastoma
Neuroblastoma
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02044-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor?

Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation

CPSF6 links alternative polyadenylation to metabolism adaption in hepatocellular carcinoma progression

ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer

The non-canonical mechanism of ER stress-mediated progression of prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer